查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肺炎治療藥的全球市場:市場規模 - 各治療藥物，各流通管道，各年齡層，感染各類型，各地區展望，競爭策略，各市場區隔預測(～2032年)
市場調查報告書
商品編碼
1159579

肺炎治療藥的全球市場:市場規模 - 各治療藥物，各流通管道，各年齡層，感染各類型，各地區展望，競爭策略，各市場區隔預測(～2032年)

Pneumonia Therapeutics Market Size- By Therapeutics, By Distribution Channel, By Age Group, By Infection Type - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 256 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球肺炎治療藥的市場規模，預計至2032年達到426億2,000萬美元，以8.3％的年複合成長率成長。

由於肺炎的盛行率增加，肺炎治療藥，成為擴大全球市場的重要要素。還有在預測期間內，預計社區型肺炎的頻率增加，市場擴大掛上(放上)刺激。同時，對醫藥品和疫苗嚴格的規則被制定，變成市場擴大的阻礙因素。

本報告提供全球肺炎治療藥市場相關調查，市場動態，市場變數及預測，各治療藥、流通管道、年齡層、感染類型、地區的市場分析，企業簡介等相關資訊。

目錄

第1章 簡介

  • 調查範圍
  • 市場區隔分析

第2章 調查手法

  • 調查資料來源
  • 市場規模的估計
  • 資料的三角測量

第3章 摘要整理

第4章 市場動態

  • 促進因素，阻礙因素，機會，課題的分析
    • 促進因素
    • 阻礙因素
    • 機會
    • 課題
  • 全球肺炎治療藥市場上COVID-19的影響

第5章 市場變數及預測

  • SWOT分析
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 社會形勢
    • 技術形勢
    • 環境形勢
    • 法律上的形勢
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商的威脅
    • 競爭企業間的敵對關係
  • 熱圖分析

第6章 全球肺炎治療藥市場:各治療藥物，2019年～2032年(100萬美元)

  • 預防疫苗
  • 治療藥
    • 抗菌藥
    • 抗病毒藥物
    • 抗真菌藥物

第7章 全球肺炎治療藥市場:各流通管道，2019年～2032年(100萬美元)

  • 醫院
  • 醫藥品經銷商
  • 其他

第8章 全球肺炎治療藥市場:各年齡層，2019年～2032年(100萬美元)

  • 兒童
  • 成人
  • 老年人

第9章 全球肺炎治療藥市場:各感染類型，2019年～2032年(100萬美元)

  • 院內肺炎(HAP)
  • 社區型肺炎(CAP)
  • 人工呼吸器相關肺炎(VAP)

第10章 全球肺炎治療藥市場:各地區，2019年～2032年(100萬美元)

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他的歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他的亞太地區
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中東、非洲
    • 沙烏地阿拉伯王國
    • 阿拉伯聯合大公國
    • 其他的中東、非洲

第11章 企業簡介

  • Abbott Laboratories
    • 企業概要
    • 財務預測
    • 產品概要
    • 最近的開發
  • Bayer AG
  • Eli Lilly & Company
  • Glaxosmithkline Plc.
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Limited
簡介目錄
Product Code: HLCA2217

Global Pneumonia Therapeutics Market Overview:

According to SPER Market Research, the Global Pneumonia Therapeutics Market is estimated to reach USD 42.62 billion by 2032 with a CAGR of 8.3%.

An infection that affects the lower respiratory system is pneumonia. Additionally, pneumonia exhibits symptoms including shortness of breath, fever, chest discomfort, nausea, and vomiting. Alveoli, the lungs' air sacs, are filled with fluid or pus in pneumonia, which results in inflammation. It is frequently found in children and the elderly and is mostly brought on by microorganisms including fungi, bacteria, viruses, and parasites. It mainly affects persons with low immune systems.

The increased prevalence of pneumonia is a significant factor driving the expansion of the global market for therapies treating the condition. Additionally, throughout the anticipated period, an increase in the frequency of community-acquired pneumonia is anticipated to fuel market expansion. Additionally, it is anticipated that an increase in product releases following FDA clearance would assist the sector to generate the most income. Additionally, it is anticipated that a rise in clinical trials for the R&D of vaccines and medicinal compounds would support industrial expansion in the next years. The establishment of strict rules for pharmaceuticals and vaccines, however, impedes market expansion.

Impact of COVID-19 on the Global Pneumonia Therapeutics Market

On January 30, 2021, the World Health Organization designated the COVID-19 outbreak a public health emergency of global significance. A person with COVID-19 is especially vulnerable to pneumonia, which can result in wheezing and an accumulation of mucus in the alveoli. This is anticipated to fuel the market for pneumonia treatments. Additionally, it is anticipated that growth in R&D for the treatment of pneumonia associated with COVID-19 would help the market to produce significant revenue throughout the projection period. However, the COVID-19 shortage of workers as well as resource restrictions are anticipated to have a detrimental effect on the industry's growth throughout the projection period. In addition, the industry expansion has been slowed by the installation of strict government restrictions governing lockdown. Additionally, it is urgent to develop fresh products that can aid in the fight against COVID-19. Because of this, the market for pneumonia treatments is expected to produce more money throughout the forecast period.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Access, By Component, By Type, By End User

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Atos SE, Alioth LLC, Cardcom Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.

Global Pneumonia Therapeutics Market Segmentation:

By Therapeutics: Based on the Therapeutics, Global Pneumonia Therapeutics Market is segmented as; Prevention Vaccines, Treatment Drugs {Antibacterial Drugs (Macrolide, Quinolones, Aminopenicillins, Macrolides, B-lactamase inhibitors, Cephalosporins, Tetracyclines, Glycopeptide antibiotics, Carbapenems, Others), Antiviral Drugs, Antifungal Drugs}.

By Distribution Channel: Based on the Distribution Channel, Global Pneumonia Therapeutics Market is segmented as; Hospitals, Pharmaceutical Stores, Others.

By Age Group: Based on the Age Group, Global Pneumonia Therapeutics Market is segmented as; Pediatric, Adult and Geriatric.

By Infection Type: Based on the Infection Type, Global Pneumonia Therapeutics Market is segmented as; Hospital-acquired pneumonia, Community-acquired pneumonia, Ventilator-associated pneumonia.

By Region: Due to rising geriatric populations, an ageing population, and an increase in both adult and paediatric multidrug resistance, North America had the largest revenue share and is predicted to keep it throughout the forecast period. These factors reinforce the need for development and rising R&D activities.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Pneumonia Therapeutics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Pneumonia Therapeutics Market, By Therapeutics, 2019-2032 (USD Million)

  • 6.1 Prevention Vaccines
  • 6.2 Treatment Drugs
    • 6.2.1 Antibacterial Drugs
      • 6.2.1.1 Macrolide
      • 6.2.1.2 Quinolones
      • 6.2.1.3 Aminopenicillins
      • 6.2.1.4 Macrolides
      • 6.2.1.5 B-lactamase inhibitors
      • 6.2.1.6 Cephalosporins
      • 6.2.1.7 Tetracyclines
      • 6.2.1.8 Glycopeptide antibiotics
      • 6.2.1.9 Carbapenems
      • 6.2.1.10 Others
    • 6.2.2 Antiviral Drugs
    • 6.2.3 Antifungal Drugs

7. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)

  • 7.1 Hospitals
  • 7.2 Pharmaceutical Stores
  • 7.3 Others

8. Global Pneumonia Therapeutics Market, By Age Group, 2019-2032 (USD Million)

  • 8.1 Pediatric
  • 8.2 Adult
  • 8.3 Geriatric

9. Global Pneumonia Therapeutics Market, By Infection Type, 2019-2032 (USD Million)

  • 9.1 Hospital-acquired pneumonia (HAP)
  • 9.2 Community-acquired pneumonia (CAP)
  • 9.3 Ventilator-associated pneumonia (VAP)

10. Global Pneumonia Therapeutics Market, By Region, 2019-2032 (USD Million)

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 United Kingdom
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Rest of South America
  • 10.5 Middle East & Africa
    • 10.5.1 Kingdom of Saudi Arabia
    • 10.5.2 United Arab Emirates
    • 10.5.3 Rest of Middle East & Africa

11. Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Company details
    • 11.1.2 Financial outlook
    • 11.1.3 Product summary
    • 11.1.4 Recent developments
  • 11.2 Bayer AG
    • 11.2.1 Company details
    • 11.2.2 Financial outlook
    • 11.2.3 Product summary
    • 11.2.4 Recent developments
  • 11.3 Eli Lilly & Company
    • 11.3.1 Company details
    • 11.3.2 Financial outlook
    • 11.3.3 Product summary
    • 11.3.4 Recent developments
  • 11.4 Glaxosmithkline Plc.
    • 11.4.1 Company details
    • 11.4.2 Financial outlook
    • 11.4.3 Product summary
    • 11.4.4 Recent developments
  • 11.5 Lupin Pharmaceuticals, Inc.
    • 11.5.1 Company details
    • 11.5.2 Financial outlook
    • 11.5.3 Product summary
    • 11.5.4 Recent developments
  • 11.6 Merck KGAA
    • 11.6.1 Company details
    • 11.6.2 Financial outlook
    • 11.6.3 Product summary
    • 11.6.4 Recent developments
  • 11.7 Novartis AG
    • 11.7.1 Company details
    • 11.7.2 Financial outlook
    • 11.7.3 Product summary
    • 11.7.4 Recent developments
  • 11.8 Pfizer, Inc.
    • 11.8.1 Company details
    • 11.8.2 Financial outlook
    • 11.8.3 Product summary
    • 11.8.4 Recent developments
  • 11.9 Sanofi S.A.
    • 11.9.1 Company details
    • 11.9.2 Financial outlook
    • 11.9.3 Product summary
    • 11.9.4 Recent developments
  • 11.10 Teva Pharmaceuticals Industries Limited
    • 11.10.1 Company details
    • 11.10.2 Financial outlook
    • 11.10.3 Product summary
    • 11.10.4 Recent developments